Neurogene Statistics

Total Valuation

Neurogene has a market cap or net worth of $219.78 million. The enterprise value is -$80.20 million.

Market Cap	219.78M
Enterprise Value	-80.20M

Important Dates

The next estimated earnings date is Friday, May 9, 2025, before market open.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

Neurogene has 14.26 million shares outstanding. The number of shares has increased by 277.22% in one year.

Current Share Class	14.26M
Shares Outstanding	14.26M
Shares Change (YoY)	+277.22%
Shares Change (QoQ)	+14.84%
Owned by Insiders (%)	11.43%
Owned by Institutions (%)	57.31%
Float	4.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	292.66
Forward PS	n/a
PB Ratio	0.74
P/TBV Ratio	0.71
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 20.84, with a Debt / Equity ratio of 0.04.

Current Ratio	20.84
Quick Ratio	20.65
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6,883.75

Financial Efficiency

Return on equity (ROE) is -30.28% and return on invested capital (ROIC) is -19.71%.

Return on Equity (ROE)	-30.28%
Return on Assets (ROA)	-18.49%
Return on Invested Capital (ROIC)	-19.71%
Return on Capital Employed (ROCE)	-25.77%
Revenue Per Employee	$8,645
Profits Per Employee	-$702,280
Employee Count	107
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-49.78%
50-Day Moving Average	14.48
200-Day Moving Average	29.40
Relative Strength Index (RSI)	61.58
Average Volume (20 Days)	369,644

Short Selling Information

The latest short interest is 2.86 million, so 20.05% of the outstanding shares have been sold short.

Short Interest	2.86M
Short Previous Month	2.44M
Short % of Shares Out	20.05%
Short % of Float	58.63%
Short Ratio (days to cover)	7.67

Income Statement

In the last 12 months, Neurogene had revenue of $925,000 and -$75.14 million in losses. Loss per share was -$4.28.

Revenue	925,000
Gross Profit	-3.58M
Operating Income	-82.61M
Pretax Income	-55.44M
Net Income	-75.14M
EBITDA	-79.36M
EBIT	-82.61M
Loss Per Share	-$4.28

Full Income Statement

Balance Sheet

The company has $312.41 million in cash and $12.43 million in debt, giving a net cash position of $299.98 million or $21.03 per share.

Cash & Cash Equivalents	312.41M
Total Debt	12.43M
Net Cash	299.98M
Net Cash Per Share	$21.03
Equity (Book Value)	310.38M
Book Value Per Share	20.89
Working Capital	300.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$70.60 million and capital expenditures -$808,000, giving a free cash flow of -$71.41 million.

Operating Cash Flow	-70.60M
Capital Expenditures	-808,000
Free Cash Flow	-71.41M
FCF Per Share	-$5.01

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-8,930.27%
Pretax Margin	-8,123.68%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neurogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-277.22%
Shareholder Yield	n/a
Earnings Yield	-34.19%
FCF Yield	-32.49%

Analyst Forecast

The average price target for Neurogene is $54.00, which is 255.73% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$54.00
Price Target Difference	255.73%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	127.54%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Neurogene has an Altman Z-Score of 10.46 and a Piotroski F-Score of 2.

Altman Z-Score	10.46
Piotroski F-Score	2